Daraxonrasib

A new pancreatic cancer drug, Daraxonrasib, has doubled median survival rates for patients with advanced metastatic disease, earning a standing ovation at a major oncology conference. The breakthrough…

Revolution Medicines presented complete Phase 3 data for daraxonrasib at ASCO 2026, showing the drug cut the risk of death by 60% and nearly doubled median overall survival to 13.2 months versus 6.7 m…